Alnylam Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alnylam Presents Positive Results From KARDIA-2 Phase 2 Study Of Zilebesiran At ACC

Alnylam Presents Positive Results From KARDIA-2 Phase 2 Study Of Zilebesiran At ACC
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Alnylam pharmaDennis riedlAmerican college of cardiologyAlnylam pharmaceuticals incAnnual scientificCardiology annual scientific session

Tracking Baillie Gifford s 13F Portfolio – Q4 2023 Update

Tracking Baillie Gifford s 13F Portfolio – Q4 2023 Update
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesPacira biosciencesAlnylam pharmaPetrobras brasileiroBaillie giffordAbcellera biologicsJohn vincentAkili incMoody corpModerna incZillow groupCloudflare incMicrosoft corpIllumina incCopa holdingsDexcom inc

Alnylam Pharma (ALNY) Announces Transition of Chief Legal Officer

Alnylam Pharma (ALNY) Announces Transition of Chief Legal Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Indranil franchiniCompany executive viceAlnylam pharmaExecutive vice presidentChief legal officerSeparation date

Alnylam Pharma Falls On Decision Not To Pursue Patisiran Clinical Trial As FDA Denies Approval

Alnylam Pharmaceuticals, Inc. (ALNY) shares are down more than 5 percent on Monday morning trade after FDA, in its complete response letter or CRL, cited insufficient evidence of clinical meaningfulness for Patisiran for the treatment of Cardiomyopathy of ATTR Amyloidosis.

Alnylam pharmaceuticals incAlnylam pharmaceuticalsAlnylam pharmaStock alert

Biotech Stocks Facing FDA Decision In September 2023

As August draws to a close, let's turn our attention to the list of companies eagerly anticipating the FDA's verdict in September..

United statesAmylyx pharma relyvrioOcuphire pharma nyxolAlnylam pharmaPharma neffyBiolinerx aphexdaRoche holdingSierra oncology incAlnylam pharmaceuticals incUnited states to saptalis pharmaceuticalsEuropean unionOcuphire pharma incPharmaceuticals incAppili therapeutics incBrainstorm cell therapeutics incBiolinerx ltd